Cyclosporine nephrotoxicity in type 1 diabetic patients A 7-year follow-up study

OBJECTIVE - To evaluate kidney function 7 years after the end of treatment with cyclosporine A (CsA) (initial dosage of 9.3 tapered off to 7.0 mg.kg(- 1).day(-1)) in young patients (mean age 20 years) with newly diagnosed type 1 diabetes participating in a randomized, double-blind, placebo-controlled CsA trial. RESEARCH DESIGN AND METHODS - tn this study, 21 patients received CsA for 1 2.5 +/- 4.0 months (mean +/- SD) and 19 patients received placebo for 14.4 +/- 3.8 months. The two groups were similar with regard to mean arterial bl ood pressure (BP), urinary albumin excretion rate (UAER), serum creatinine, and estimated glomerular filtration rate (GFR [Cockcroft and Gault]) at in itiation of CsA treatment (baseline). HbA(1c) (mean +/- SEM) during 7 years of follow-up was also the same: 8.7 +/- 0.4 vs. 8.3 +/- 0.4% in the CsA an d placebo groups, respectively RESULTS - During the 7 years after cessation of study medication, two CsA g roup patients and one control patient were lost to follow-up. One placebo-t reated patient developed IgA nephropathy (biopsy proven) and was excluded. Four CsA-treated patients developed persistently elevated UAER >30 mg/24 h (n = 3 with microalbuminuria), whereas all the 17 placebo-treated patients had normal UAER (<30 mg/24 h) after 7 years of follow-up. At the end of fol low-up, the CsA group had a more pronounced rise in UAER: 2.5-fold (95% CI 1.4-4.5) higher than baseline values vs. 1.1-fold (0.7-1.7) in the placebo- treated group (P < 0.05). Estimated GFR (ml.min(-1) 1.73 m(-2)) declined fr om baseline to end of follow-up (1994) by 6.3 +/- 6.0 in the former CsA gro up, whereas it rose by 7.4 +/- 5.0 in the placebo group (P = 0.05). In 1994 , 24-h blood pressure was nearly the same: 131/77 +/- 4/2 vs. 127/75 +/- 2/ 2 mmHg (NS) in the CsA and placebo groups, respectively. Five randomly sele cted CsA-treated patients had a kidney biopsy performed shortly after the C sA treatment was stopped. Interstitial fibrosis/tubular atrophy and/or arte riolopathy were present in two subjects who both subsequently developed per sistent microalbuminuria. CONCLUSIONS - The results of our 7-year follow-up study suggested that shor t-lasting CsA treatment in young, newly diagnosed type 1 diabetic patients accelerated the rate of progression in UAER and tended to induce a loss in kidney function. Longer term follow-up is mandatory to clarify whether CsA- treated patients are at increased risk of developing clinical nephropathy.